Radioactive MIBG for stubborn nerve tumors
Part of Cancer clinical trials.
This trial gives a radioactive drug (131I-MIBG) that targets and kills certain nerve tumor cells. It is for people whose neuroblastoma or related tumors have not responded to standard treatments or have come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of nerve cancer (like neuroblastoma or pheochromocytoma) that stopped responding to standard treatment or came back.
- Your tumor must show up on a special scan (MIBG) done in the last 6 weeks.
- You are older than 1 year and can safely handle radiation precautions.
- You have your own blood stem cells stored (or you will get a lower dose of the study drug).
- Your liver, kidneys, and blood counts are within safe limits based on recent lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for children or young adults already in specific brain tumor or neuroblastoma trials. It looks at how a type of imaging (MCT) might help doctors better understand and treat these cancers.
This trial studies a radioactive medicine called iodine I-131 MIBG to shrink tumors that take up MIBG. It may help people whose neuroblastoma or malignant pheochromocytoma/paraganglioma has come back, progressed, or not responded to standard treatment.
This trial uses a special radioactive medicine (131I-MIBG) to target and kill cancer cells in people with neuroblastoma or pheochromocytoma that has not responded to other treatments. It may help shrink tumors or slow the disease, and you'll receive a stem cell transplant afterward to help your body recover.
This trial tests a combination of a radioactive drug (MIBG) that targets neuroblastoma cells, with two other drugs that may help the radiation work better. It is for children and young adults with high-risk neuroblastoma that has come back or not gone away after standard treatment.
This early-phase trial tests a new drug called IR-101 for children with high-risk neuroblastoma that has come back or isn't responding to treatment. It aims to see if the drug is safe and can help shrink tumors that show up on a MIBG scan.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.